NCT05816499View on ClinicalTrials.gov

Cadonilimab in Patients (Pts) With Advanced Non-small Cell Lung Cancer (NSCLC)

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

February 16, 2023

Primary Completion Date

December 30, 2024

Study Completion Date

December 30, 2025

Conditions
NSCLC Stage IVNSCLC Stage IIIBNSCLC Stage IIIC
Interventions
DRUG

Cadonilimab

Given IV, 10mg/kg Q3W

DRUG

Anlotinib

oral，6mg/8mg/10mg qd 2W/3W

DRUG

Docetaxel

Given IV, 60-75mg/m2 Q3W

Trial Locations (5)

200000

Shanghai Chest Hospital, Shanghai

230000

lejie Cao, Hefei

266000

Jing Wang, Qingdao

Zhuang Yu, Qingdao

310000

Jianya Zhou, Hangzhou

All Listed Sponsors
lead

Shanghai Chest Hospital

OTHER

collaborator

The Affiliated Hospital of Qingdao University

OTHER

collaborator

Anhui Provincial Hospital

OTHER_GOV

collaborator

Zhejiang University

OTHER